of Integrase Inhibitors
|
|
- Reynard Wood
- 6 years ago
- Views:
Transcription
1 Resistance Characteristics of Integrase Inhibitors Dr Charlotte CHARPENTIER Laboratoire de Virologie Hôpital Bichat-Claude Bernard INSERM UMR IAME Université Paris Diderot
2 Plan 1 st generation: Raltegravir (RAL) and Elvitegravir (EVG/c) 2 nd generation: Dolutegravir (DTG) Epidemiology of resistance to integrase inhibitors Ongoing: Bictegravir (BIC) and Cabotegravir (CAB)
3 Plan 1 st generation: Raltegravir (RAL) and Elvitegravir (EVG/c) 2 nd generation: Dolutegravir (DTG) Epidemiology of resistance to integrase inhibitors Ongoing: Bictegravir (BIC) and Cabotegravir (CAB)
4 In vitro selection experiments RAL EVG
5 RAL and EVG mean FC of single mutation SDMs
6 RAL: analysis of resistance in the BENCHMRK trials Phase 3 clinical trials conducted in highly-experienced patients with resistant viruses: RAL + Optimized Background Treatment VL <400 c/ml in 78 % of patients at W16 (vs 42 % in placebo group) Genotypic resistance to RAL in 60 % of patients in VF with available integrase sequence at VF Three major resistance mutations: codons 143, 148 and 155 Emergence of resistance mainly occurred during the first years of the trial, rarely after the third year Cooper et al., NEJM, 2008; Eron et al., Lancet Infect Dis, 2013
7 Combined analysis of resistance at W96 in the TDF and TAF/FTC/EVG/c trials in ARV-naïve patients Patients meeting criteria for resistance analysis E/c/F/TAF (n = 866) E/c/F/TDF (n = 867) 19 (2 %) 16 (2 %) Resistance mutations 10 (1.2 %) 8 (0.9 %) RT mutations 10 (1.2 %) 7 (0.8 %) M184I/V 9 6 K65N/R 2 3 K70R 1 1 Integrase mutations 8 (0.9 %) 5 (0.6 %) T66A/I/V 2 0 E92Q 4 2 Q148R 1 2 N155H/S Resistance development (%) E/C/F/TAF E/C/F/TDF S48 S96 S48 S96 Patients with criteria for resistance analysis Emergence of resistance Distribution of resistance mutations at time of VF FTC FTC TAF TDF EVG EVG Rare selection of resistance and in similar proportions in the TAF and TDF arms Callebaut et al., IHDRW 2016, Abs. 32; CROI 2016, Abs. 496
8 Y143R +T97A Y143C +T97A N155H +E92Q Q148R +G140S Q148H +G140S Y143R +T97A Y143C +T97A N155H +E92Q Q148R +G140S Q148H +G140S Switch from 155 to 148 resistance profile RAL Fold-Change 100 Maximum Fold Change Viral replicative capacity (%) 50 0 Fransen et al., Antimicrob Agents Chemother, 2009 Fransen et al., CROI 2009, Abs. 69
9 Major mutations and secondary mutations Major mutations Q148H/K/R N155H Y143C/H/R Secondary mutations G140A/S, E138K E92Q, L74M, V151I, G163R T97A, E92Q, E157Q Nucleic Acids Research, 2009 Secondary mutations: restoration of viral replicative capacity and of resistance level RAL and EVG Low genetic barrier to resistance High level of cross resistance
10 Plan 1 st generation: Raltegravir (RAL) and Elvitegravir (EVG/c) 2 nd generation: Dolutegravir (DTG) Epidemiology of resistance to integrase inhibitors Ongoing: Bictegravir (BIC) and Cabotegravir (CAB)
11 In vitro selection experiments DTG
12 DTG, RAL and EVG mean FC against RAL & EVG-related single mutation SDMs
13 Resistance Fold-Change to RAL and DTG according to integrase mutations profiles 143 and 155: most favorable resistance profiles for DTG activity 148 (specially 140/148 double mutants): worst resistance profile for DTG activity Underwood et al., IHDRW 2013, Abs. 85
14 VIKING-3 trial: virological response at D8 and W24 according to baseline integrase mutations VIKING-3 is a single-arm, open-label phase III study in which therapy-experienced adults with INI-resistant virus received DTG 50 mg bid while continuing their failing regimen (without raltegravir or elvitegravir) through day 7, after which the regimen was optimized with 1 fully active drug and DTG continued IN mutation Day 8 response Decline in VL (log 10 c/ml) Full response a Week 24 response < 50 c/ml n Median n (%) n n (%) No Q (92 %) (79 %) Q b (71 %) 20 9 (45 %) Q148 + >2 b (45 %) 9 1 (11 %) a Full response: decline in HIV-1 RNA > 1 log 10 c/ml or 50 c/ml at D8 b L74I, E138A/K/T and G140A/C/S Vavro et al., IHVDRW 2013, Abs. 29
15 Change from baseline in plasma HIV-1 RNA at day 8 (log 10 c/ml) VIKING-3 trial: relationship between baseline integrase mutations and D8 virological response Baseline INI resistant mutation category Q148 + > 2 Q N155 Y143 > 2 primary mutations Primary not detected Baseline FC IN IC 95 relative to wild type virus for DTG Vavro et al., IHVDRW 2013, Abs. 29
16 le meilleur de la CROI 2014 Impact of mutations selected by RAL or EVG on DTG activity Assessment of different Q148 mutants on the phenotypic susceptibility to DTG Phenotypic assays using clinical isolates and site-directed mutants Susceptibility of Q148 + E138 mutants and Q148 + G140 to DTG (fold-change) Susceptibility of clinical isolates with Q148H + G140S to DTG (fold-change) n = 127 Median fold-change = 4.3 Range = Q148K mutation associated with other integrase mutations showed a higher of susceptibility to DTG than Q148H/R viruses 1 Mutations 66, 74, 92, 97, 138, 143, 147, 155, and 163 excluded High variability of DTG susceptibility to G140S + Q148H double mutants Huang et al., CROI 2014, Abs. 595
17 DTG in ARV-naïve patients To date, no INI or NRTI resistance mutations detected at VF in the DTG arms of the phase 3 randomized clinical trials: - SPRING: 2 NRTI + DTG vs. RAL - SINGLE: ABC/3TC + DTG vs. EFV - FLAMINGO: 2 NRTI + DTG vs. DRV/r But: - Very few VF, sequences performed on the first plasma samples at VF, only known INI resistance mutations analyzed
18 SAILING trial: resistance analysis through W24 (1) Phase 3 randomized clinical trial, ARV-experienced patients but INI-naïve with VL >400 c/ml (2x) or >1000 c/ml (1x) DTG 50 mg qd, n (%) RAL 400 mg bid, n (%) VF week 24 (VL > 400 c/ml) 14 (4) 34 (9) BL and VF data 9 (64) 27 (80) Any emergent IN substitutions 2 (22) 9 (33) Emergence of IN mutations associated with development of resistance to INI class L68V, L74M, E92Q, T97A, G140A/S, Y143C/H/R, Q148H/R, V151I, N155H, E157Q, G163K 0 9 (33) R263K, R263R/K 2 (22) 0 DTG, RAL and EVG Fold-Change IC 50 Strain IN substitution / FC IC 50 DTG RAL EVG NL432 a R263K HXB2 V260I RVA b R263K V260I/R263K a HeLa-CD4 cells, 3-day assay, B-gal readout, b MT4 cells, 5-day assay, cell tier glow readout Underwood et al., IHDRW 2013, Abs. 21
19 SAILING trial: resistance analysis through W24 (2) Underwood et al., IHDRW 2013, Abs. 21
20 le meilleur de l IAS-EACS 2015 SAILING trial: resistance analysis after W48 Patient 1 VL (log 10 c/ml) Patient 2 VL (log 10 c/ml) Patient 3 VL (log 10 c/ml) Subtype C TDF + DRV/r PSS = 2; GSS = c/ml c/ml c/ml Subtype A ABC + 3TC PSS = 2; GSS = c/ml 407 c/ml Subtype B TDF + FTC PSS = 2; GSS = c/ml 622 c/ml 386 c/ml C 24h DTG (ng/ml): W4 = 1 780, W48 = C 24h DTG: W4 = 1 114, W24 <20, W48 = C 24h DTG (ng/ml): W4 = 360, W24 = 220, W48 = 30 BL W72 BL W108 BL W120 W132 VL (c/ml) IN Mutation WT I60L, T97A, N155H DTG fold change RAL fold change RC (% WT) ND ND VL (c/ml) IN Mutation WT N155H DTG fold change RAL fold change RC (% WT) ND ND VL (c/ml) IN Mutation WT A49G, S230R, R263K A49G, S230R, R263K DTG fold change RAL fold change RC (% WT) 20 % 7 % 12 % Underwood et al., EUHHW 2015, Abs. 6
21 le meilleur de la CROI 2017 First case report of integrase mutation selection at VF of a DTG-based first-line regimen 45 years old man, HIV diagnosis with inaugural pneumocystosis: CD4 = 78/mm 3, VL = c/ml (6.3 log 10 c/ml) Baseline resistance genotype RT: WT; protease: E35D-L63P-A71T-V77I; integrase not performed ARV initiation: TDF/FTC + DTG in the hospital Follow-up of VL and CD4 Add DRV/r RT: M184V IN: G163E Days VL (c/ml) CD4 (/mm 3 ) Integrase ultra-deep sequencing (codons 142 to 165) Time 1 Time 2 Time 3 Wild-type Q148K I151V-G163E Silent mutation I151V G163E I151M Y143L-N144Q-P145S S147N I162M Emergence of M184V mutation in RT Emergence of I151V and G163E mutations in integrase at the second time-point Emergence of Q148K viruses: from % to 20.9 % between T2 and T3 (< 10 days) Fulcher et al., CROI 2017, Abs. 500LB
22 DTG monotherapy in switch: explored and avoided A Dutch multicenter randomized clinical trial: DOMONO trial Pooled analysis of 3 observational cohorts (Barcelona, Montréal, Munich) A monocentric observational cohort in Paris, France DOMONO trial Pooled observational cohorts French observational cohort n Number of VF 8/77 (10 %) 11/122 (9 %) 3/28 (11 %) Number of IN mutations in VF patients IN mutations 3/5 (60 %) 9/11 (82 %) 3/3 (100 %) N155H S230R R263K N155H (n=1) T97A-N155H (n=1) E92Q-N155H (n=1) Q148H-N155H (n=1) E138K-Q148K (n=1) G118R (n=2) G140S-Q148H/R (n=2) N155H L74I-E92Q E138K-G140A-Q148R Wijting et al., CROI 2017, Abs. 451LB Blanco et al., CROI 2017, Abs. 42 Katlama et al., EACS 2015, Abs. PS4/4 High rate of VF and of resistance selection, strategy definitively not recommended
23 Plan 1 st generation: Raltegravir (RAL) and Elvitegravir (EVG/c) 2 nd generation: Dolutegravir (DTG) Epidemiology of resistance to integrase inhibitors Ongoing: Bictegravir (BIC) and Cabotegravir (CAB)
24 Q148H/K/R G140A/C/S N155H Y143C/H/R E138A/K E92Q/V T66A/I/K S147G F121Y R263K le meilleur de la CROI 2014 INI resistance profiles in United States: HIV integrase sequences issued from patients experiencing a VF when receiving a RAL-based treatment INI resistance in 26 % of samples Most prevalent resistance profiles: Q148H/K/R (36 %), N155H (31 %) INI resistance mutations (n) Description of major INI resistance mutations 21 % with other mutations (n = 12) Y143 (n = 57) 20 % with other mutations (n = 27) N155 (n = 135) 35 % with other mutations (n = 54) Q148 (n = 155) 1 % single Q148H/K/R (n = 2) 79 % single Y143C/H/R (n = 45) 80 % single N155H (n = 108) 64 % Q148H/K/R + G140A/C/S (n = 99) Hurt et al., CROI 2013, Abs. 591
25 12.3 % of high level of resistance to DTG in case of major INI resistance mutations selected at time of VF when receiving a RAL-based treatment
26 National multicenter cross-sectional study n = 502 patients experiencing a VF when receiving a RAL-based treatment 71 % subtype B Median VL = 2.9 log 10 c/ml 13.9 % of resistance to DTG 39 % with INI mutation Factors associated with presence of INI resistance mutations at VF: - VL at time of VF - GSS <2
27 le meilleur de VIH 2016 ANRS study: INI resistance prevalence in patients experiencing a VF with an INI (1) INI mutations prevalence at VF (%) National multicenter cross-sectional study n = 439 patients experiencing a VF when receiving an INI-based treatment since October % subtype B Median VL = 3.0 log 10 c/ml INI resistance mutation in 36 % of patients 22 %: 1 INI resistance mutation 8 %: 2 INI resistance mutations 6 %: > 2 INI resistance mutations 23 % of resistance to DTG qd and 3.5 % to DTG bid in patients failing RAL or EVG Marcelin et al., HIV Glasgow 2016, Abs. O332
28 le meilleur de VIH 2016 ANRS study: INI resistance prevalence in patients experiencing a VF with an INI (2) Subgroup analysis of patients in VF of a DTG first-line regimen (n = 41) - Treated in median since 0.4 years (IQR = ) - Median VL at VF: 2.7 log 10 c/ml (IQR = ) - No major INI resistance mutation at VF - Mutations detected at VF: L74M (n = 1) and E157Q (n = 2) INI resistance interpretation (%) DTG bid DTG qd RAL EVG Susceptible, n (%) 39 (95) 39 (95) 39 (95) 39 (95) Possible resistance, n (%) 2* (5) 2* (5) - - Resistance, n (%) 0 0 2* (5) 2* (5) * 2 patients with single E157Q Subtype B (n = 2) Present at baseline in 1 case (ongoing BL sequencing for the second patient) E157Q and L74M are polymorphisms naturally present in some ARV-naïve patients Marcelin et al., HIV Glasgow 2016, Abs. O332
29 E157Q mutation: polymorphic and acquired Prevalence of 5 % in chronically-infected ARV-naïve patients Differential distribution of the E157Q polymorphism among HIV-1 subtypes: Subtype B: 2.3 %, CRF02_AG: 7.5 % Saladini et al., EHDRW 2017, Abs. 72 Selected in vivo in patients failing RAL-based treatment Assoumou et al., IAS 2017, Abs. TUPEC0851 Malet et al., Antimicrob Agents Chemother, 2008 J Antimicrob Chemother, 2009 Case report of a non virological response to a DTG-based regimen Danion et al., J Antimicrob Chemother, 2015
30 E157Q mutation: in vitro analysis Virus from the non response to a DTGbased regimen Phenotypic analysis of 7 clinical isolates - 3 fold increase of the strand-transfer activity - 9 fold factor of resistance compared with WT virus - 1 virus at the limit of the RAL biological cut-off (FC=1.5) - All 7 clinical samples susceptible to DTG Danion et al., J Antimicrob Chemother, 2015 Saladini et al., EHDRW 2017, Abs. 72 Role of the E157Q polymorphism not clearly elucidated
31 INI acquired drug resistance The rate of selection of resistance mutations at time of VF is not so high, between 26 % and 39 % in the US and French studies Do we know everything on INI resistance mechanisms? - Rare resistance profiles? - Genotypic determinants of resistance outside integrase?
32 Newly described and rare resistance RAL pathways Fold Change to RAL and DTG EC50 values were obtained from cell culture assays and IC50 values were obtained from assays using recombinant IN proteins. Each value represents the mean+sd for three independent experiments. These data show that G118R and F121Y represent new RAL resistance pathways that may also be involved in DTG resistance Mutations L74F and V75I: a case report IN: WT VL (c/ml) CD4 (/mm 3 ) RAL TDF/FTC IN: L74F V75I DRV IN: L74V-V75I I60M-V72I RAL EVG DTG CAB L74F V75I L74F-V75I 4.5 8, I60M-L74F-V75I V72I-L74F-V75I I60M-V72I-L74F-V75I Codons that may indirectly affect the Mg 2+ coordination position The I60M mutation restores the viral RC J Antimicrob Chemother, 2015 Hachiya et al., CROI 2017, Abs
33 le meilleur de la CROI 2017 A high level of resistance to DTG associated with mutations outside integrase Objective: in vitro selection experiments but under very high concentrations of DTG ( 500 nm) in order to force the virus to select DTG resistance Results Detection of resistant virus between M2 and M3 of culture Integrase sequencing: no emergent mutation Whole genome sequencing: mutations in 3 PPT region (nef gene) Position 9053 // Reference sequence Mutant virus sequence C // G G G G G G T // G C A G T - 5 AAAAGAAAAG(G9069C)(G9070A)G(G9072T)(G9073del) PPT mutated virus Wild-type virus In vitro analysis High level of resistance to DTG but also RAL and EVG associated with low viral RC (10 %) Able to produce newly infections of MT4 cells Conclusion: mutations selected in vitro by DTG and located outside the integrase gene can confer themselves very high-level of resistance to all known INI DTG (nm) Malet et al., CROI 2017, Abs. 499
34 Transmitted drug resistance to INI National epidemiological survey (ANRS virology network, n = 33 centers, n = 597 patients) Chronically-infected ARV-naïve patients diagnosed between October 2015 and March 2016 % TDR prevalence by drug class % IN mutations : IAS list ** : IAS list + E157Q Two patients with transmission of major INI resistance mutations (Q148) High prevalence of INI transmitted drug resistance mutations Pre-therapeutic integrase resistance testing is recommended in France Assoumou et al., IAS 2017, Abs. TUPEC0851
35 Plan 1 st generation: Raltegravir (RAL) and Elvitegravir (EVG/c) 2 nd generation: Dolutegravir (DTG) Epidemiology of resistance to integrase inhibitors Ongoing: Bictegravir (BIC) and Cabotegravir (CAB) formerly GSK
36 le meilleur de VIH 2016 In vitro activity of bictegravir (BIC) against INI-resistant viruses Q148H/R + G140A/S Susceptible Reduced susceptibility WT Resistance FC < 2,5 2,5 < FC < 10 FC > 10 Susceptible 92Q+157Q 97A +74M 143C +68V 143R +68,74 155H +74M 155H+157Q 148R+138A 155H+163R 148R+138K WT Double mutant Reduced susceptibility Resistance FC < 2,5 2,5 < FC < 10 FC > 10 BIC DTG EVG RAL Susceptible Q148H/R + G140A/C/S + 1 WT +E138K +G163K +E138K 143 +E138K +T97A +E138K +L74M +E138A +T97A +L74M +E138K Resistance FC < 2,5 2,5 < FC < 10 FC > 10 Susceptible Reduced susceptibility WT Reduced susceptibility Single mutant Resistance E92Q E92Q 92 T97A 143 F121Y Y143R Y143R 143 Y143C N155H 143 FC < 2,5 2,5 < FC < 10 FC > 10 White et al., EWHDR 2016, Abs. O-01
37 le meilleur de la CROI 2017 Phase 2 trial comparing BIC versus DTG (+ TAF/FTC) in first-line - Week 48 results VL < 50 c/ml, ITT snapshot VL < 50 c/ml; difference, % (95 % CI) BIC + FTC/TAF (n = 65) W24 DTG + FTC/TAF (n = 33) W48 Favors DTG + FTC/TAF Favors BIC + FTC/TAF W24 2,9-8,5 14, W48 6,4-6 18, Virological success 3 6 Virological failure 0 0 No data Virological success Virological failure 3 No data -12 % 0 12 % No NRTI or INI resistance detected Change in CD4/mm 3 at W48: vs (p = 0.16) Sax et al., CROI 2017, Abs. 41 ; Lancet HIV 2017
38 le meilleur de la CROI 2015 LATTE trial: resistance analysis of a VF in the CAB 10 mg + RPV arm at W48 LATTE trial: RCT assessing the efficacy of a dual-therapy in maintenance with RPV + CAB (10 mg, 30 mg or 60 mg) IM Plasma VL (log 10 c/ml) CAB + TDF/FTC CAB + RPV Weeks Q148R INT E138Q RT Sub-optimal plasma concentrations of CAB and RPV 48 Phenotypic susceptibility to INI of SDM (Fold-change) Mutation CAB DTG RAL EVG Y143C Y143H Y143R Q148H Q148K > Q148R N155H Highest FC to Q148K/R viruses with CAB than with DTG (factor 4), suggesting that CAB might be more impacted by the Q148K/R than DTG Dudas et al., IHDRW 2015, Abs. 13
39 le meilleur de la CROI 2017 Resistance analysis in macaques treated with CAB LA during primary infection (1) Objective: modeling in the macaque the risk of emergence of resistance associated with the initiation of CAB LA during a recent undiagnosed HIV infection Methods 6 Rhésus macaques Infection by intravenous of RT-SHIV virus with SIVmac239 integrase 3 monthly IM injections of CAB LA at the dose of 50 mg/kg RT-SHIV Infection RNA RT-SHIV+ CAB LA injections ELISA+ M1 M2 Radzio et al., CROI 2017, Abs. 84
40 le meilleur de la CROI 2017 Resistance analysis in macaques treated with CAB LA during primary infection (2) Macaque # Resistance analysis by INT sequencing Integrase mutations 1 st day of resistance mutations detection 10D181 E92Q-Q124R-G140R 81 Compartment Blood, rectum, vagina E92G 143 Blood CH54 G118R-A122T 57 Blood, rectum 01D520 None A122T 162 Blood CJ92 I72T-S135A 32 Blood E92Q: SIV (EVG: FC 4; CAB: FC = 2-4); HIV-1 (RAL: FC > 5; DTG: FC > 30) E92G: SIV (not described); HIV-1 (EVG: FC 10) G118R: SIV (DTG: FC = 11; RAL: FC = 3; EVG: FC = 10); HIV-1 (DTG, RAL and EVG: FC = 5-20) Phenotypic tests ongoing Conclusions Frequent selection of resistance Presence of resistant viruses in compartments (rectum, vagina) risk of resistance transmission Radzio et al., CROI 2017, Abs. 84
41 To summarize: 1 st generation: Raltegravir (RAL) and Elvitegravir (EVG/c) - Low genetic barrier to resistance - Cross resistance Selection of mutations in 40 % of VF 2 nd generation: Dolutegravir (DTG) - Higher genetic barrier to resistance than RAL/EVG but not a PI (cf monotherapy strategy) - bid dosing is required after a VF under INI first generation - Q148+G140 double mutants, most prevalent mutants at VF, showed an increased phenotypic FC to DTG
42 Virology Pr Diane Descamps Dr Charlotte Charpentier Dr Florence Damond Dr Nadhira Houhou-Fidouh Dr Houria Ichou Dr Lucile Larrouy Dr Vincent Mackiewicz Dr Marine Perrier Dr Benoit Visseaux Dr Quentin Le Hingrat Mélanie Bertine Gilles Collin Alice Mariaggi Sarah Peerbaccus Alexandre Storto Infectious Diseases Pr Yazdan Yazdanpanah Pr Elisabeth Bouvet Pr Sophie Matheron Pr Patrick Yéni Dr Véronique Joly Dr Roland Landman Dr Sylvie Lariven Dr Xavier Lescure Dr Christophe Rioux Dr Paul Loubet Clinical Pharmacology Dr Gilles Peytavin Dr Minh Lê Clinical trials Dr Bao-Chau Phung Dr Adriana Pinto Dr Ornella Cabras Cindy Godard Djamila Rahli Françoise Louni Malikhone Chansombat Zelie Julia
Resistance Characteristics of Integrase Inhibitors
Resistance Characteristics of Integrase Inhibitors Madrid, November 2016 Jonathan M Schapiro, MD National Hemophilia Center, Israel Stanford University School of Medicine, USA Disclaimer Presentation includes
More informationResistance to Integrase Strand Transfer Inhibitors
NORTHWEST AIDS EDUCATION AND TRAINING CENTER Resistance to Integrase Strand Transfer Inhibitors David Spach, MD Clinical Director, Northwest AETC Professor of Medicine, Division of Infectious Diseases
More informationTransmission of integrase resistance HIV
Transmission of integrase resistance HIV Charles Boucher, MD, PhD Clinical Virology, Dept. Viroscience, Erasmus Medical Center, Erasmus Universiy, The Netherlands Major resistance mutations (Stanford)
More informationUpdate on HIV Drug Resistance. Daniel R. Kuritzkes, MD Division of Infectious Diseases Brigham and Women s Hospital Harvard Medical School
Update on HIV Drug Resistance Daniel R. Kuritzkes, MD Division of Infectious Diseases Brigham and Women s Hospital Harvard Medical School Learning Objectives Upon completion of this presentation, learners
More informationRESEARCH B/F/TAF in Treatment-Naïve HIV-1 and HIV-1 RNA Suppressed Switch Patients
RESEARCH B/F/TAF in Treatment-Naïve HIV-1 and HIV-1 RNA Suppressed Switch Patients Kirsten White Gilead Sciences, Inc., Foster City, CA Background Bictegravir (BIC; B) is a novel, unboosted integrase strand
More informationResistance Post Week 48 in ART-Experienced, Integrase Inhibitor-Naïve Subjects with Dolutegravir (DTG) vs. Raltegravir (RAL) in SAILING (ING111762)
Resistance Post Week 48 in ART-Experienced, Integrase Inhibitor-Naïve Subjects with Dolutegravir (DTG) vs. Raltegravir (RAL) in SAILING (ING111762) MR Underwood 1, F DeAnda 1, D Dorey 2, K Hightower 1,
More informationIntegrase Strand Transfer Inhibitors on the Horizon
NORTHWEST AIDS EDUCATION AND TRAINING CENTER Integrase Strand Transfer Inhibitors on the Horizon David Spach, MD Clinical Director, Northwest AETC Professor of Medicine, University of Washington Presentation
More informationDisclosures. Introduction to ARV Drug Resistance New Clinicians Workshop 12/9/16. Introduction. ARS Question
Disclosures Introduction to ARV Drug Resistance New Clinicians Workshop I have no disclosures Susa Coffey, MD Division of HIV, ID and Global Medicine ARS Question Which resistance test do you order for
More informationVIKING STUDIES Efficacy and safety of dolutegravir in treatment-experienced subjects
VIKING STUDIES Efficacy and safety of dolutegravir in treatment-experienced subjects IL/DLG/0040/14 June 2014 GSK (Israel) Ltd. Basel 25, Petach Tikva. Tel-03-9297100 Medical information service: il.medinfo@gsk.com
More informationDisclosures. Introduction to ARV Drug Resistance New Clinicians Workshop. Introduction. ARS Question
Disclosures Introduction to ARV Drug Resistance New Clinicians Workshop I have no disclosures Susa Coffey, MD Division of HIV, ID and Global Medicine ARS Question Which resistance test do you order for
More informationDisclosures. Introduction to ARV Drug Resistance New Clinicians Workshop. Introduction. ARS Question 12/6/2017
Disclosures Introduction to ARV Drug Resistance New Clinicians Workshop I have no disclosures Susa Coffey, MD Division of HIV, ID and Global Medicine ARS Question Which resistance test do you order for
More informationPharmacokinetic, Safety and Efficacy of Darunavir/Ritonavir in HIV+ Pregnant Women
Pharmacokinetic, Safety and Efficacy of Darunavir/Ritonavir in HIV+ Pregnant Women DR MINH LÊ PHARMACO-TOXICOLOGY DEPARTMENT APHP, HÔPITAL BICHAT-CLAUDE BERNARD PARIS, FRANCE ABSTRACT #O_01 17TH INTERNATIONAL
More informationCL Vavro, 1 J Huang, 2 C Avatapally, 1 S Min, 1 and M Ait-Khaled 3. GlaxoSmithKline: 1 Research Triangle Park,NC, USA; 2 Toronto, ON, Canada; 3
Durable Efficacy and Limited Integrase Resistance Evolution in Subjects Receiving Dolutegravir After Failing Prior Integrase Inhibitor (INI) Regimens: Week 48 Results from VIKING-3 CL Vavro, 1 J Huang,
More informationHIV Treatment: New and Veteran Drugs Classes
HIV Treatment: New and Veteran Drugs Classes Jonathan M Schapiro, MD National Hemophilia Center Stanford University School of Medicine Rome, March 2013 Overview Many excellent antiretroviral agents are
More informationAcquired INSTI Resistance. Daniel R. Kuritzkes, M.D. Division of Infectious Diseases Brigham and Women s Hospital Harvard Medical School
Acquired INSTI Resistance Daniel R. Kuritzkes, M.D. Division of Infectious Diseases Brigham and Women s Hospital Harvard Medical School Disclosures The speaker has received consulting honoraria, speaker
More informationMutations to Integrase Inhibitors in real life
Mutations to Integrase Inhibitors in real life González-Domenech CM, Viciana I, Sena Corrales G, Delgado M, De la Torre J, Torres Tortosa M, Téllez F, Jarilla F, Clavijo E, Santos J BACKGROUND INSTI Block
More informationDisclosure. Companies/funders. Research grants (to the institute) Merck, Gilead, Janssen, ViiV. Speakers fee. Viiv, Abvie, Gilead.
Disclosure Companies/funders Research grants (to the institute) Merck, Gilead, Janssen, ViiV Speakers fee Viiv, Abvie, Gilead Other Co-owner/Scientific director Virology Education Integration Insertion
More informationPr Vincent Calvez. Faculté de Médecine Sorbonne Université UMR Sorbonne Université Inserm 1136 Service de Virologie Hôpital Pitié-Salpêtrière
Pr Vincent Calvez Faculté de Médecine Sorbonne Université UMR Sorbonne Université Inserm 1136 Service de Virologie Hôpital Pitié-Salpêtrière Pretreatment HIV Drug Resistance in the START Study Using Next
More informationCROI 2013: New Drugs for Treatment and PrEP
NORTHWEST AIDS EDUCATION AND TRAINING CENTER CROI 2013: New Drugs for Treatment and PrEP Brian R. Wood, MD Medical Director, NW AETC Project ECHO Assistant Professor of Medicine, University of Washington
More informationThe next generation of ART regimens
The next generation of ART regimens By Gary Maartens Presented by Dirk Hagemeister Division of Clinical Pharmacology UNIVERSITY OF CAPE TOWN IYUNIVESITHI YASEKAPA UNIVERSITEIT VAN KAAPSTAD Current state
More informationAre the current doses of ARV correct. Richard Elion MD Associate Adjunct Clinical Professor of Medicine Johns Hopkins School of Medicine
Are the current doses of ARV correct Richard Elion MD Associate Adjunct Clinical Professor of Medicine Johns Hopkins School of Medicine Can we lower doses of HIV meds safely? Consensus Panel in Alexandria
More informationVIKING STUDIES. Efficacy and safety of dolutegravir. treatment-experienced subjects
VIKING STUDIES Efficacy and safety of dolutegravir treatment-experienced subjects (DTG) in UK/DLG/0083/14e(2) Date of preparation: February 2017 Prescribing information is available at the end of this
More informationCase 1 continued. Case 1 (cont) 12/8/16. MMAH Debate Panel Thursday, December 8, Case 1
MMAH Debate Panel Thursday, December 8, 2016 Case 1 HPI 55 yo man with newly diagnosed HIV initiates care in your clinic. His CD4+ cell count is 600, with HIV VL=90,000 copies/ml. He is asymptomatic at
More informationResistance to novel integrase inhibitors
Resistance to novel integrase inhibitors Dr Anne-Geneviève Marcelin Virology - Pitié-Salpêtrière Hospital INSERM U943, UPMC HIV integrase Dr Anne-Geneviève Marcelin 1 HIV Integration: A Six Step Process
More informationDisclosures (last 12 months)
HIV Research What s in the Pipeline? Samir K. Gupta, MD, MS Division of Infectious Diseases Indiana University School of Medicine Disclosures (last 12 months) Independent research grant funding by NIH/NHLBI,
More informationReduced Drug Regimens
Dr. Jose R Arribas @jrarribas Financial disclosures JOSE R ARRIBAS Research Support: Speaker s Bureau: Viiv, Janssen, Abbvie, BMS, Gilead, MSD Board Member/Advisory Panel: Merck, Gilead Stock/Shareholder:
More informationINTERGRASE INHIBITORS- WHAT S NEW?
INTERGRASE INHIBITORS- WHAT S NEW? Professor Margaret Johnson Royal Free London Foundation Trust October 2018 Targeting the HIV life-cycle NEW HIV VIRON MATURATION CO-RECEPTOR BINDING FUSION BUDDING CD4
More informationWhat is the Virologic Support for Two-Drug Regimens?
What is the Virologic Support for Two-Drug Regimens? Daniel R. Kuritzkes, M.D. Division of Infectious Diseases Brigham and Women s Hospital Harvard Medical School Disclosures The speaker has received consulting
More informationLê MP, 1,2 Cournil A, 3 Kouanfack C, 4 Lem S, 5 Le Gac S, 5 Delaporte E, 3 Peytavin G, 1,2 for the NAMSAL study group
Lê MP, 1,2 Cournil A, 3 Kouanfack C, 4 Lem S, 5 Le Gac S, 5 Delaporte E, 3 Peytavin G, 1,2 for the NAMSAL study group 1 AP-HP, Hopital Bichat, Pharmacology-Toxicology, Paris, France, 2 IAME, UMR 1137,
More informationVirological suppression and PIs. Diego Ripamonti Malattie Infettive - Bergamo
Virological suppression and PIs Diego Ripamonti Malattie Infettive - Bergamo Ritonavir-boosted PIs Boosted PIs: 3 drugs in one The intrinsic antiretroviral activity Viral suppression and high baseline
More informationAntiretroviral Treatment Strategies: Clinical Case Presentation
Antiretroviral Treatment Strategies: Clinical Case Presentation Department of Internal Medicine, Far Eastern Memorial Hospital, New Taipei City, Taiwan Chia-Jui, Yang M.D Disclosure No conflicts of interests.
More informationBon Usage des Antirétroviraux dans l Infection par le VIH
Bon Usage des Antirétroviraux dans l Infection par le VIH Pr. Jean-Michel Molina CHU St Louis, Assistance Publique Hôpitaux de Paris, INSERM U941 et Université Paris 7 Diderot, France 1 Liens d Intérêt
More informationHIV-2 Therapy. Ricardo Jorge Camacho KU Leuven, Rega Institute for Medical Research, Leuven, Belgium
HIV-2 Therapy Ricardo Jorge Camacho KU Leuven, Rega Institute for Medical Research, Leuven, Belgium World distribution ~1.000.000 2.000.000 people infected in West Africa Highest prevalence : Guinea-Bissau
More informationHistory (August 2010) Therapy for Experienced Patients. History (September 2010) History (November 2010) 12/2/11
(August 2010) Therapy for Experienced Patients Hiroyu Hatano, MD, MHS Assistant Professor of Medicine University of California San Francisco Medical Management of AIDS December 2011 42M HIV (CD4=450, VL=6250,
More informationDoes Resistance Still Matter? Daniel R. Kuritzkes, M.D. Division of Infectious Diseases Brigham and Women s Hospital Harvard Medical School
Does Resistance Still Matter? Daniel R. Kuritzkes, M.D. Division of Infectious Diseases Brigham and Women s Hospital Harvard Medical School Disclosure The speaker serves as a consultant to, and has received
More informationCROI 2017 Highlights What s New in Antiretrovirals (Part 2)
Mountain West AIDS Education and Training Center CROI 2017 Highlights What s New in Antiretrovirals (Part 2) Ann Collier, MD This presentation is intended for educational use only, and does not in any
More informationIntroduction to HIV Drug Resistance. Kevin L. Ard, MD, MPH Massachusetts General Hospital Harvard Medical School
Introduction to HIV Drug Resistance Kevin L. Ard, MD, MPH Massachusetts General Hospital Harvard Medical School Objectives 1. Describe the epidemiology of HIV drug resistance in sub-saharan Africa. 2.
More informationThe Integrase Inhibitor Drug Class: A Comparative Clinical Review
The Integrase Inhibitor Drug Class: A Comparative Clinical Review Ian Frank Professor of Medicine University of Pennsylvania Philadelphia, PA USA franki@pennmedicine.upenn.edu Disclosure Gilead, ViiV/GlaxoSmithKline:
More informationOptimizing Clinical Utility of Integrase Inhibitors. Anton Pozniak MD FRCP
Optimizing Clinical Utility of Integrase Inhibitors Anton Pozniak MD FRCP INSTIs-Characteristics Rapid viral load decline Low rates resistance/ Transmitted Resistance Less chance of side effects Less pills,
More informationSecond-Line Therapy NORTHWEST AIDS EDUCATION AND TRAINING CENTER
NORTHWEST AIDS EDUCATION AND TRAINING CENTER Second-Line Therapy David Spach, MD Clinical Director, Northwest AETC Professor of Medicine, Division of Infectious Diseases University of Washington Presentation
More informationDolutegravir: Pros and Cons (Are There Any Cons?)
Mountain West AIDS Education and Training Center Dolutegravir: Pros and Cons (Are There Any Cons?) Brian R. Wood, MD Assistant Professor of Medicine, University of Washington Medical Director, MW AETC
More informationWHEN TO START? CROI 2015: Focus on ART
CROI 215: Focus on ART FORMATTED: 4-1-15 Washington, DC: May 13, 215 Roy M. Gulick, MD, MPH Gladys and Roland Harriman Professor of Medicine Chief, Division of Infectious Diseases Weill Cornell Medical
More informationAntiviral Activity of Tenofovir Alafenamide against HIV-1 with Thymidine Analog Mutation(s) and M184V
Antiviral Activity of Tenofovir Alafenamide against HIV-1 with Thymidine Analog Mutation(s) and M184V Christian Callebaut, PhD Gilead Sciences, Foster City, CA, USA HIV DART AND EMERGING VIRUSES 12/08/2016
More informationTwo-drug combination passage among dolutegravir, rilpivirine, elvitegravir and Lamivudine
Two-drug combination passage among dolutegravir, rilpivirine, elvitegravir and Lamivudine T, Yoshinaga, S. Miki, T. Seki, T. Fujiwara Shionogi & Co., Ltd., Osaka, Japan Background A two-drug regimen may
More information2 nd Line Treatment and Resistance. Dr Rohit Talwani & Dr Dave Riedel 12 th June 2012
2 nd Line Treatment and Resistance Dr Rohit Talwani & Dr Dave Riedel 12 th June 2012 Overview Basics of Resistance Treatment failure Strategies to manage treatment failure Mutation Definition: A change
More informationIntegrase strand-transfer inhibitors primary resistance in patients with acute/recent HIV infection
Integrase strand-transfer inhibitors primary resistance in patients with acute/recent HIV infection Juan Ambrosioni, David Nicolás, Christian Manzardo, Fernando Agüero, José Luis Blanco, Maria del Mar
More informationARVs in Development: Where do they fit?
The picture can't be displayed. ARVs in Development: Where do they fit? Daniel R. Kuritzkes, M.D. Division of Infectious Diseases Brigham and Women s Hospital Harvard Medical School Disclosures The speaker
More informationResistance Analyses of Integrase Strand Transfer Inhibitors within Phase 3 Clinical Trials of Treatment-Naive Patients
Viruses 2014, 6, 2858-2879; doi:10.3390/v6072858 Review OPEN ACCESS viruses ISSN 1999-4915 www.mdpi.com/journal/viruses Resistance Analyses of Integrase Strand Transfer Inhibitors within Phase 3 Clinical
More informationACTHIV 2018: A State-of-the-Science Conference for Frontline Health Professionals
ACTHIV 2018: A State-of-the-Science Conference for Frontline Health Professionals ACTHIV 2018: A State-of-the-Science Conference for Frontline Health Professionals Are You Ready? New Drugs Are on the Way!
More informationManagement of ART Failure. EACS Advanced HIV Course 2015 Dr Nicky Mackie
Management of ART Failure EACS Advanced HIV Course 2015 Dr Nicky Mackie Outline Defining treatment success Defining treatment failure Reasons for ART failure Management of ART failure Choice of second
More informationVirological failure to Protease inhibitors in Monotherapy is linked to the presence of signature mutations in Gag without changes in HIV-1 replication
Virological failure to Protease inhibitors in Monotherapy is linked to the presence of signature mutations in Gag without changes in HIV-1 replication Oscar Blanch-Lombarte Rome, 7-9 June, 2017 European
More informationDidactic Series. CROI New Antiretroviral Therapies. Daniel Lee, MD Clinical Professor of Medicine UCSD Medical Center Owen Clinic July 14, 2016
Didactic Series CROI 2016 - New Antiretroviral Therapies Daniel Lee, MD Clinical Professor of Medicine UCSD Medical Center Owen Clinic July 14, 2016 This project is supported by the Health Resources and
More informationClinical support for reduced drug regimens. David A Cooper The University of New South Wales Sydney, Australia
Clinical support for reduced drug regimens David A Cooper The University of New South Wales Sydney, Australia Clinical support for reduced drug regimens First line optimisation Virological failure New
More informationDRUGS IN PIPELINE. Pr JC YOMBI UCL-AIDS REFERENCE CENTRE BREACH Sept 27, 2015
DRUGS IN PIPELINE Pr JC YOMBI UCL-AIDS REFERENCE CENTRE BREACH Sept 27, 2015 N(t)RTI The Development of TAF TAF Delivers the High Potency of TDF While Minimizing Off- Target Kidney and Bone Side Effects
More informationResistance Workshop. 3rd European HIV Drug
3rd European HIV Drug Resistance Workshop March 30-April 1 st, 2005 Christine Hughes, PharmD Clinical Associate Professor Faculty of Pharmacy & Pharmaceutical Sciences University of Alberta Tenofovir resistance
More informationPanelists Melanie Thompson Jeffrey Lennox Wendy Armstrong Jonathan Li
Slide 1 of 51 Interactive ART Cases From the Clinic(ians): Case-Based Panel Discussion Michael S. Saag, MD Professor of Medicine Associate Dean for Global Health Jim Straley Chair in AIDS Research University
More informationDr Carole Wallis, PhD Medical Director, BARC-SA Head of the Specialty Molecular Division, Lancet Laboratories, South Africa
Dr Carole Wallis, PhD Medical Director, BARC-SA Head of the Specialty Molecular Division, Lancet Laboratories, South Africa Transmitted drug resistance Resistance patterns in first-line failures in adults
More informationImproving PI drug resistance scores. Jens Verheyen, MD Institute of Virology University Duisburg-Essen
Improving PI drug resistance scores Jens Verheyen, MD Institute of Virology University Duisburg-Essen Overview Why can all PI drug resistance scores be improved? Do we still need to improve PI drug resistance
More informationPr Vincent Calvez Dpt of Virology Hôpital Pitié-Salpêtrière France ANRS
French national survey of resistance to integrase inhibitors shows high differences of resistance selection rate in case of virological failure in a context of routine hospital care (ANRS AC11 virology
More informationFrench National survey of resistance to integrase inhibitors in a context of routine hospital care (ANRS AC11 virology network)
French National survey of resistance to integrase inhibitors in a context of routine hospital care (ANRS AC11 virology network) Marcelin AG ; Grude M; Charpentier C; Bellecave, P; Le Guen, L; Pallier,
More informationDrug Resistance to Integrase Strand Transfer Inhibitors in HIV-1 Chilean Patients. Frequency and evolution between the years 2013 and 2016.
Drug Resistance to Integrase Strand Transfer Inhibitors in HIV-1 Chilean Patients. Frequency and evolution between the years 2013 and 2016. Sidgman F. 1, Valdés F. 1, Ferrer P. 2, Maureira V. 1, Afani
More informationCROI 2017 Review: Novel ART Strategies
Mountain West AIDS Education and Training Center CROI 2017 Review: Novel ART Strategies Brian R. Wood, MD Assistant Professor of Medicine Medical Director, Mountain West AETC ECHO Telehealth March 2, 2017
More informationSINGLE. Efficacy and safety of dolutegravir (DTG) in treatment-naïve subjects
SINGLE Efficacy and safety of dolutegravir (DTG) in treatment-naïve subjects SE/HIV/0023/14 January 2014 PHASE III DTG TRIALS IN TREATMENT-NAÏVE ADULT SUBJECTS WITH HIV SINGLE 1 N=833 Phase III non-inferiority,
More informationSwitching antiretroviral therapy to safer strategies based on integrase inhibitors. Pedro Cahn
Switching antiretroviral therapy to safer strategies based on integrase inhibitors Pedro Cahn Disclosures Research Grants: Abbvie-Merck-Richmond-ViiV Advisory boards: Merck-Sandoz-ViiV Switching in Virologically
More informationSwitching ARV Regimens: Managing Toxicity and Improving Tolerability; Switches & Class-Sparing Approaches
Switching ARV Regimens: Managing Toxicity and Improving Tolerability; Switches & Class-Sparing Approaches Harry W. Lampiris, MD Chief, Infectious Disease Section, San Francisco VA Medical Center Professor
More informationTim Horn Deputy Executive Director, HIV & HCV Programs Treatment Action Group NASTAD Prevention and Care Technical Assistance Meeting Washington, DC
Tim Horn Deputy Executive Director, HIV & HCV Programs Treatment Action Group NASTAD Prevention and Care Technical Assistance Meeting Washington, DC July 19, 2017 Pipeline is robust! Several drugs, coformulations,
More informationPersistent low-level HIV-1 RNA between 20 and 50 copies/ml in antiretroviral-treated patients: associated factors and virological outcome
J Antimicrob Chemother 2012; 67: 2231 2235 doi:10.1093/jac/dks191 Advance Access publication 29 May 2012 Persistent low-level HIV-1 RNA between 20 and 50 copies/ml in antiretroviral-treated patients: associated
More informationREASONS FOR DISCONTINUATION OF DUAL THERAPY WITH DOLUTEGRAVIR AND RILPIVIRINE
REASONS FOR DISCONTINUATION OF DUAL THERAPY WITH DOLUTEGRAVIR AND RILPIVIRINE R. Montejano, N. Stella-Ascariz, S. Garcia-Bujalance, JI. Bernardino, V. Hontañon, R. Mican, Montes M, E. Valencia, J. González,
More informationCabotegravir + Rilpivirine as Long-Acting Maintenance Therapy: LATTE-2 Week 32 Results
Slide 1 Cabotegravir + Rilpivirine as Long-Acting Maintenance Therapy: LATTE-2 Week 32 Results David A. Margolis, 1 Juan Gonzalez-Garcia, 2 Hans-Jürgen Stellbrink, 3 Joe Eron, 4 Yazdan Yazdanpanah, 5 Sandy
More informationMore Options, Some Opinions Initial Therapies for HIV Judith S. Currier, MD
More Options, Some Opinions Initial Therapies for HIV Judith S. Currier, MD More Options, Some Opinions: Initial Therapies for HIV Judith S. Currier, MD University of California Los Angeles Los Angeles,
More informationDavid Cluck, PharmD, BCPS, AAHIVP Associate Professor of Pharmacy Practice Office 326 Phone
David Cluck, PharmD, BCPS, AAHIVP Associate Professor of Pharmacy Practice Office 326 Phone 423-439-6245 Email cluckd@etsu.edu Recall newly approved antiretrovirals and their respective place in therapy
More informationState of the ART: Integrase Inhibitors Clinical Data. Juan Berenguer Hospital General Universitario Gregorio Marañón (IiSGM) Madrid, Spain
State of the ART: Integrase Inhibitors Clinical Data Juan Berenguer Hospital General Universitario Gregorio Marañón (IiSGM) Madrid, Spain Disclosures Consulting fees and honoraria Gilead, Janssen, MSD,
More informationNovel mutations located outside the integrase gene confer HIV-1 integrase strand-transfer inhibitors resistance.
Novel mutations located outside the integrase gene confer HIV-1 integrase strand-transfer inhibitors resistance. Dr Olivier Delelis Pr Anne-Geneviève Marcelin 1 Resistance to Anti-Integrases Raltegravir(RAL)
More informationSwitching antiretroviral therapy to safer strategies based on integrase inhibitors
Switching antiretroviral therapy to safer strategies based on integrase inhibitors Dr Paddy Mallon UCD HIV Molecular Research Group UCD School of Medicine paddy.mallon@ucd.ie UCD School of Medicine & Medical
More informationCabotegravir Long-Acting (LA) Injectable Nanosuspension Bill Spreen, for ViiV Healthcare & GSK Development Team. 17 th HIV-HEPPK June 2016
Cabotegravir Long-Acting (LA) Injectable Nanosuspension Bill Spreen, for ViiV Healthcare & GSK Development Team RPV CAB CAB RPV 1 June 2016 Cabotegravir Long-Acting Nanosuspension CAB is an investigational
More informationWhat is the virological support for reduced drug regimens?
What is the virological support for reduced drug regimens? Pr Anne-Genevieve Marcelin Pitié-Salpêtrière Hospital UMR 1136 University Pierre et Marie Curie Paris, France Disclosure of Personal and Commercial
More informationAbstract #8 15th EU Meeting on HIV & Hepatitis (7-9 June 2017)
Epidemiological study of Doravirine associated resistance mutations in HIV-1- infected treatment-naïve patients from two large databases in France and Italy Anne-Genevieve Marcelin, Maria Mercedes Santoro,
More informationRoy M. Gulick, MD, MPH Rochelle Belfer Professor in Medicine Weill Cornell Medicine New York, New York
Antiretroviral Therapy: Investigational New Drugs and New Strategies Roy M. Gulick, MD, MPH Rochelle Belfer Professor in Medicine Weill Cornell Medicine New York, New York FORMATTED: MM/DD/YY Antiretroviral
More informationManagement of Treatment-Experienced Patients: New Agents and Rescue Strategies. Joel E. Gallant, MD, MPH Johns Hopkins University School of Medicine
Management of Treatment-Experienced Patients: New Agents and Rescue Strategies Joel E. Gallant, MD, MPH Johns Hopkins University School of Medicine When to Modify Therapy! Studies to date show better responses
More informationReduced drug regimens. Josep M Llibre Infectious Diseases & Fight AIDS Fndn Univ Hosp Germans Trias i Pujol Badalona, Barcelona
Reduced drug regimens Josep M Llibre Infectious Diseases & Fight AIDS Fndn Univ Hosp Germans Trias i Pujol Badalona, Barcelona jmllibre@flsida.org 9th IAS Conference on HIV Science (IAS 2017) 23 26 July
More informationUpdate on HIV-1 Drug Resistance and Tropism Testing
Update on HIV-1 Drug Resistance and Tropism Testing Daniel R. Kuritzkes, MD Section of Retroviral Therapeutics Brigham and Women s Hospital Harvard Medical School ACTHIV 2011: A State-of-the-Science Conference
More informationClinical Management of Resistance. AMJ Wensing, MD, PhD
Clinical Management of Resistance AMJ Wensing, MD, PhD Changing treatment paradigm First Line Second Line? New First Line North America Western Europe: Eastern Europe Africa mix South America mix More
More informationInvestigational Approaches to Antiretroviral Therapy
Investigational Approaches to Antiretroviral Therapy Rajesh T. Gandhi, MD Massachusetts General Hospital Professor of Medicine Harvard Medical School Boston, Massachusetts Learning Objectives After attending
More informationHIV Treatment Update. Anton Pozniak Consultant Physician, Director of HIV Services Chelsea and Westminster Hospital, London
HIV Treatment Update Anton Pozniak Consultant Physician, Director of HIV Services Chelsea and Westminster Hospital, London Guidelines Nuke sparing Nukes Efavirenz placement as the gold standard ARV Role
More informationTransmitted and Acquired HIV Drug Resistance in Latin America. Dr. Luis Enrique Soto Ramírez MEXICO
Transmitted and Acquired HIV Drug Resistance in Latin America Dr. Luis Enrique Soto Ramírez MEXICO Disclosure Advisory boards and speaker for: Abbvie GSK/ViiV MSD Roche Diagnostics OVERVIEW The development
More informationHIV Virology & Resistance
Themes Viral load Tropism Drug resistance HIV Virology & Resistance Anna Maria Geretti Institute of Infection & Global Health The HIV Virology Timeline HIV-1 isolated HIV replicates at high levels throughout
More informationA case, and some pharmacological considerations. from the perspective of a virologist. Anna Maria Geretti University of Liverpool, United Kingdom
A case, and some pharmacological considerations. from the perspective of a virologist Anna Maria Geretti University of Liverpool, United Kingdom 1 Case History: Mr RS 53-year-old male Diagnosed HIV positive
More informationViiV Healthcare investor & analyst update
ViiV Healthcare investor & analyst update 15 February 2017 David Redfern, GSK Chief Strategy Officer and Chairman, ViiV Healthcare Dr. Dominique Limet, Chief Executive Officer, ViiV Healthcare Dr. John
More informationSTRIBILD (aka. The Quad Pill)
NORTHWEST AIDS EDUCATION AND TRAINING CENTER STRIBILD (aka. The Quad Pill) Brian R. Wood, MD Medical Director, NW AETC ECHO Assistant Professor of Medicine, University of Washington Presentation prepared
More informationHIV 101. Applications of Antiretroviral Therapy
HIV 101. Applications of Antiretroviral Therapy Michael S. Saag, MD Professor of Medicine Associate Dean for Global Health Jim Straley Chair in AIDS Research University of Alabama at Birmingham Birmingham,
More informationCrafting an ART Regimen for Initiation or Salvage: Are NRTI s Necessary?
NORTHWEST AIDS EDUCATION AND TRAINING CENTER Crafting an ART Regimen for Initiation or Salvage: Are NRTI s Necessary? Brian R. Wood, MD Assistant Professor of Medicine, University of Washington Medical
More informationWhat are the most promising opportunities for dose optimisation?
What are the most promising opportunities for dose optimisation? Andrew Hill Liverpool University, UK Global Financial Crisis How can we afford to treat 15-30 million people with HIV in the future? Lowering
More information11/7/2016. Antiretroviral Therapy Strategies. Learning Objectives. After attending this presentation, participants will be able to:
Antiretroviral Therapy Strategies FORMATTED: 1/14/16 Joel E. Gallant, MD, MPH Medical Director of Specialty Services Southwest CARE Center Santa Fe, New Mexico Adjunct Professor of Medicine The Johns Hopkins
More informationInvestigational Approaches to Antiretroviral Therapy
Investigational Approaches to Antiretroviral Therapy Rajesh T. Gandhi, MD Massachusetts General Hospital Professor of Medicine Harvard Medical School Boston, Massachusetts Learning Objectives After attending
More informationThe Dawn of the TLD Era
The Dawn of the TLD Era 20th September 2018 Mark Siedner Africa Health Research Institute Harvard Medical School Outline: A Primer on Dolutegravir Do we really need more HIV drugs? The case for a new first-line
More informationTreating HIV: When the Guidelines Don t Fit. Joel Gallant, MD, MPH. Southwest CARE Center Santa Fe, New Mexico
Treating HIV: When the Guidelines Don t Fit Joel Gallant, MD, MPH Southwest CARE Center Santa Fe, New Mexico Johns Hopkins University School of Medicine University of New Mexico School of Medicine Disclosures
More informationTreating HIV in 2018 Interactive Cases From the Clinic(ians)
Slide 1 of 51 Treating HIV in 2018 Interactive Cases From the Clinic(ians) Michael S. Saag, MD Professor of Medicine Associate Dean for Global Health Jim Straley Chair in AIDS Research University of Alabama
More informationPharmacologic Characteristics and Delivery Options for Integrase Inhibitors
Pharmacologic Characteristics and Delivery Options for Integrase Inhibitors Courtney V. Fletcher, Pharm.D. Dean, College of Pharmacy Professor, Department of Pharmacy Practice and Division of Infectious
More informationShould We Be Worried about HIV Resistance in Prevention Trials?
Should We Be Worried about HIV Resistance in Prevention Trials? John W Mellors, MD MTN Regional Meeting Cape Town, SA 25 Sept 2018 YES HIV Drug Resistance? HIV Drug Resistanc e NRTI + NNRTI Resistance
More informationAntiretroviral Therapy: What to Start
FLOWED: 05-14-2015 Chicago, IL: May 18, 2015 Antiretroviral Therapy: What to Start Eric S. Daar, MD Professor of Medicine David Geffen School of Medicine University of California Los Angeles Los Angeles,
More information